[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100356002":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":18,"responsibleParty":34,"collaborators":18,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":18,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":18,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":59,"whyStopped":18,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":18},{"fullName":5,"class":6},"West China Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intravenous iron group","EXPERIMENTAL","Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.",[13],"Drug: Intravenous iron isomaltose anhydride",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Clinical management, including surgical procedures, anesthesia, and perioperative management, are performed in accordance with standard clinical practice.",null,[20],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":18},"DRUG","Intravenous iron isomaltose anhydride",[9],[25],{"name":26,"affiliation":27,"role":28},"Ren Liao, M.D.","Department of Anesthesiology, West China Hospital, Sichuan University","PRINCIPAL_INVESTIGATOR",[30],{"name":26,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","+86-18980602177","liaoren7733@163.com",{"type":28,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Ren Liao","Associate Professor","100356002","short-term-intravenous-iron-isomaltose-anhydride-for-ida-100356002",false,"NCT03915327","Short-term Intravenous Iron Isomaltose Anhydride for IDA","Short-term Use of Intravenous Iron Isomaltose Anhydride for Preoperative Anemic Patients Undergoing Orthopedic Surgery: a Prospective, Randomized, Controlled Study","Inclusion Criteria:\n\n* Age \\> 14 years;\n* Sign and date the \"informed consent form\"\n\nExclusion Criteria:\n\n* Pregnant or lactation;\n* Drug abuse, including but not limited to opioids, amphetamines, ice, ketamine, etc.;\n* History of anaphylaxis to oral or intravenous iron;\n* Nervous system diseases such as peripheral neuropathy, mental illness;\n* Other conditions that the investigator deems are not suitable for the study, such as deafness, Parkinson's disease, communication disorders, etc.;\n* Participated in other clinical trials during the first three months of the study.","ALL","14 Years","99 Years",{"count":48,"type":49},1600,"ESTIMATED","INTERVENTIONAL",[52],"NA","This prospective, randomized, controlled study aims to evaluate the impact of short-term intravenous iron isomaltose anhydride on postoperative recovery and the requirement for allogeneic red blood cells (RBC) transfusion in preoperative Iron-deficiency anemia (IDA) patients receiving orthopedic surgery, thus facilitating developing a simple and effective iron supplement approach for patients' recovery.",[55],"Iron Deficiency Anemia",[57,22,58],"Iron-deficiency anemia","Preoperative","NOT_YET_RECRUITING","2024-05-03",{"date":62,"type":63},"2024-05-06","ACTUAL",{"date":65,"type":49},"2024-07-05",{"date":67,"type":49},"2029-05-31",{"name":5,"class":6}]